Ct. Attorney General Files Petition with FDA Seeking Warning on Drug - NYT

[Guest guest]

SSRI-Research@

Fri, 13 May 2005 08:30:09 -0400

[sSRI-Research] Ct. Attorney General Files Petition with FDA

Seeking Warning on Drug - NYT

 

 

 

 

Ct. Attorney General Files Petition with FDA Seeking Warning on Drug - NYT

 

Sat, 7 May 2005

 

http://www.ahrp.org/infomail/05/05/07a.php

 

Connecticut's Attorney General, Richard Blumenthal, is to be commended

for filing a citizen's petition that essentially asks the FDA to do

its job of protecting the public by issuing warnings about the

potentially lethal hazards of drugs the agency approves for marketing.

 

The drug, In this case, is an anticancer drug, Thalomid--it causes

blood clots, but that risk is not adequately disclosed to physicians

and patients.

 

Blumenthal said he took the unusual action because " it's vitally

important in light of F.D.A.'s ignoring a critical responsibility to

mandate adequate warnings and labeling. "

 

Blumenthal's petition says that there should be explicit warnings

about blood clots " and that physicians should consider giving patients

other drugs to guard against the problem. "

 

Blumenthal's petition notes that " failure to require a similar warning

here " has not worked well for patients, leaving them unnecessarily

vulnerable to potentially fatal and possibly preventable side effects. "

 

The Hebrew sages of old encouraged taking responsibility: In

circumstances where there is no leader at the helm--you, be that

leader. Richard Blumenthal filled the vacum.

 

Contact: Vera Hassner Sharav

212-595-8974

 

 

http://www.nytimes.com/2005/05/04/health/04drug.html?

 

THE NEW YORK TIMES

May 4, 2005

Petition Seeks Warning on Anticancer Medication

By GARDINER HARRIS

 

WASHINGTON, May 3 - Drug regulators have failed to warn patients that

a popular anticancer drug, Thalomid, can cause fatal blood clots,

according to a petition filed on Tuesday by the attorney general of

Connecticut, Richard Blumenthal.

 

In the petition, Mr. Blumenthal also said Celgene, the maker of

Thalomid, had increased its price so many times that patients had to

find supplies overseas, where prices are lower. The increases are

undermining a safety program mandated by the Food and Drug

Administration, Mr. Blumenthal said, and the F.D.A. should prevent

Celgene from further increases.

 

" At least one Connecticut patient almost died as a result of a blood

clot while taking Thalomid, " Mr. Blumenthal said.

 

A spokeswoman for Celgene would not comment.

 

A spokeswoman for the drug agency said it would examine the petition.

 

Mr. Blumenthal said he believed that he was the first state attorney

general to file a citizen petition, a method by which anyone can

request a specific action by the drug agency.

 

Although the New York State attorney general, Eliot Spitzer, has

helped expand the job description of attorneys general beyond arrests

in criminal cases and consumer protection actions, he has not delved

into drug labeling.

 

Suggesting that the drug agency should regulate drug prices is perhaps

even more unusual.

 

" Yes, it's a new arena, " Mr. Blumenthal said, " but one that's vitally

important in light of F.D.A.'s ignoring a critical responsibility to

mandate adequate warnings and labeling. "

 

The chairman of the International Myeloma Foundation, Dr. Brian G. M.

Durie, said he thought that most physicians were well aware of the

clotting risks. Dr. Durie said that he had not heard of any patients

going abroad to buy Thalomid.

 

Thalomid is an unusual medicine. Known generically as thalidomide, it

became infamous in the 1950's and 60's for causing thousands of

horrific birth defects in babies in Europe, where the drug was

approved for use as a sedative. Most of the affected fetuses died, but

some children were born with arms and legs that resembled flippers.

 

The drug was not approved in the United States, so American women were

spared its effects.

 

Celgene, based in Summit, N.J., initially sought approval for

thalidomide in the 90's to help treat the wasting disease associated

with AIDS. The drug caused an unusual complication in AIDS patients,

and the company was eventually able to have the drug approved to treat

just leprosy, an extremely rare condition. As a result, its sales

potential was limited.

 

After Thalomid was on the market, Celgene found that it was effective

in treating multiple myeloma, a cancer of the plasma cells in bone

marrow that affects 50,000 patients a year in the United States. Sales

soared.

 

More than 90 percent of its sales are to cancer patients, a use for

which the Food and Drug Administration has never granted formal

approval. Still, such " off label " uses of drugs are common.

 

As Thalomid became an accepted cancer treatment, Celgene increased the

price roughly fivefold in six years. The company sells a 100-milligram

capsule for $70.47 in the United States, according to Mr. Blumenthal's

petition.

 

A recent article in The Wall Street Journal found that a laboratory in

Brazil sold 100-milligram capsules of thalidomide to the Brazilian

government for 7 cents, or one-thousandth of the American price.

 

To gain approval here, the drug agency required Celgene to create an

elaborate distribution system that involved physician training and

patient education.

 

Patients have to comply with mandatory contraceptive measures.

 

The price increases undermine those controls, Mr. Blumenthal said. As

a result, the F.D.A. should prohibit Celgene from raising the price of

the medicine further, he added.

 

" Excessive prices cause people to go to illicit means of obtaining the

drug, and that thereby undermines the safety programs that are so

powerful, " Mr. Blumenthal said.

 

The drug label says patients " may have an increased incidence " of

serious clots.

 

Mr. Blumenthal's petition says the risk of such clots is well

characterized. It says that there should be explicit warnings and that

physicians should consider giving patients other drugs to guard

against the problem.

 

The petition says the Australian label has a far stronger warning

about clots.

 

The failure to require a similar warning here " has not worked well for

patients, " the petition says, " leaving them unnecessarily vulnerable

to potentially fatal and possibly preventable side effects. "

 

FAIR USE NOTICE: This may contain copyrighted (C ) material the use of

which has not always been specifically authorized by the copyright

owner. Such material is made available for educational purposes, to

advance understanding of human rights, democracy, scientific, moral,

ethical, and social justice issues, etc. It is believed that this

constitutes a 'fair use' of any such copyrighted material as provided

for in Title 17 U.S.C. section 107 of the US Copyright Law. This

material is distributed without profit.